Davis's Drug Guide
sofosbuvir/velpatasvir/voxilaprevir
General
Genetic Implications:
Pronunciation:
soe-fos-bue-vir/vel-pat-as-vir/vox-i-la-pre-vir
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Vosevi
Ther. Class.
Pharm. Class.
NS5B inhibitors
NS5A inhibitors
protease inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Sofosbuvir/velpatasvir/voxilaprevir." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir.
Vallerand AHA, Sanoski CAC, Quiring CC. Sofosbuvir/velpatasvir/voxilaprevir. Davis's Drug Guide. F.A. Davis Company; 2024. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir. Accessed December 24, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Sofosbuvir/velpatasvir/voxilaprevir. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir
Vallerand AHA, Sanoski CAC, Quiring CC. Sofosbuvir/velpatasvir/voxilaprevir [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 December 24]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - sofosbuvir/velpatasvir/voxilaprevir
ID - 110523
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110523/all/sofosbuvir_velpatasvir_voxilaprevir
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
